PFE

Pfizer
NYSE

Real-time Quotes | Nasdaq Last Sale

35.76
-0.24
-0.67%
Pre Market: 35.70 -0.06 -0.17% 05:01 09/25 EDT
OPEN
35.95
PREV CLOSE
36.00
HIGH
36.04
LOW
35.54
VOLUME
19.79M
TURNOVER
--
52 WEEK HIGH
40.97
52 WEEK LOW
27.88
MARKET CAP
198.71B
P/E (TTM)
14.55
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Vaccine news roundup - Cuomo sets up panel for separate NY review
Dr. Anthony Fauci took to Facebook Live on Thursday to assuage increasing concerns about a politicized approval process for a potential coronavirus vaccine."People are always saying, 'How do I know
Seekingalpha · 1h ago
Sanofi CEO Says COVID-19 Vaccine Development Process Accelerated, Not Side-Stepped
Sanofi SA (NASDAQ: SNY) CEO Paul Hudson said Thursday that the drugmaker is following the standard process of vaccine development with its COVID-19 candidate.
Benzinga · 5h ago
Novavax Shares Surge 7% As It Begins Late-Stage COVID-19 Vaccine Trials
Novavax, Inc (NASDAQ: NVAX) said Thursday it was launching a large-scale diverse Phase 3 study of its COVID-19 vaccine in the United Kingdom — causing a more than 7% spike in the company’s shares after the closing bell.
Benzinga · 7h ago
Novavax Starts a Phase 3 Trial of Its Covid-19 Vaccine
Barrons.com · 10h ago
Sanofi isn't cutting corners in coronavirus vaccine development despite acceleration, CEO says
"We don't feel pressure. We feel pressure to get it right and maintain the standards and to play a big part in helping people get back to normal," Sanofi CEO Paul Hudson told CNBC.
CNBC.com · 10h ago
Top U.S. health officials try to reassure people of coronavirus vaccine safety as concerns stir
There's a lot of confusion because there are mixed messages that are coming," Dr. Anthony Fauci, the director of National Institute of Allergy and Infectious Diseases, said.
CNBC.com · 12h ago
U.S. vaccine program chief backs stricter rules for emergency use of COVID-19 shot
The scientific head of the U.S. government program designed to speed development of COVID-19 vaccines said on Thursday he supports stricter rules to grant emergency use of new inoculations against the novel coronavirus. Speaking at a meeting with Black physicians and community leaders, Operation Warp
Reuters · 13h ago
Moderna Analyst On 4 Coronavirus Vaccine Program Risks
Moderna Inc (NASDAQ: MRNA) is one of the frontrunners in a crowded race to develop a vaccine against the novel coronavirus. Despite Moderna's strong positioning, an analyst at SVB Leerink said he harbors some concerns over the company's vaccine program.The Moderna Analyst: Mani Foroohar maintained
Benzinga · 14h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PFE. Analyze the recent business situations of Pfizer through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PFE stock price target is 41.79 with a high estimate of 53.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 5.56B
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Chief Executive Officer/Director
Albert Bourla
President
John Young
Chief Financial Officer/Executive Vice President
Frank D'Amelio
Corporate Executive
Angela Hwang
Chief Human Resource Officer/Executive Vice President
Dawn Rogers
Executive Vice President/Chief Technology Officer
Lidia Fonseca
Executive Vice President/Chief Compliance Officer/Chief Risk Officer
Rady Johnson
Executive Vice President/General Counsel
Douglas Lankler
Executive Vice President
Alexander Mackenzie
Executive Vice President
Sally Susman
Senior Vice President/Chief Accounting Officer/Controller
Jennifer Damico
Senior Vice President
Gordon Loh
Chief Scientific Officer
Mikael Dolsten
Lead Director/Independent Director
Shantanu Narayen
Director
Susan Desmond-Hellmann
Independent Director
Ronald Blaylock
Independent Director
W. Don Cornwell
Independent Director
Wyllie Don Cornwell
Independent Director
Joseph Echevarria
Independent Director
Wyllie Cornwell
Independent Director
Scott Gottlieb
Independent Director
Helen Hobbs
Independent Director
Susan Hockfield
Independent Director
James Kilts
Independent Director
Dan Littman
Independent Director
Suzanne Nora Johnson
Independent Director
James Quincey
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
09/24/2020
Dividend USD 0.38
11/05/2020
06/25/2020
Dividend USD 0.38
07/30/2020
04/23/2020
Dividend USD 0.38
05/07/2020
12/16/2019
Dividend USD 0.38
01/30/2020
09/24/2019
Dividend USD 0.36
11/07/2019
06/27/2019
Dividend USD 0.36
08/01/2019
04/25/2019
Dividend USD 0.36
05/09/2019
12/14/2018
Dividend USD 0.36
01/31/2019
09/27/2018
Dividend USD 0.34
11/08/2018
06/28/2018
Dividend USD 0.34
08/02/2018
04/26/2018
Dividend USD 0.34
05/10/2018
12/18/2017
Dividend USD 0.34
02/01/2018
09/27/2017
Dividend USD 0.32
11/09/2017
06/23/2017
Dividend USD 0.32
08/02/2017
04/28/2017
Dividend USD 0.32
05/10/2017
12/13/2016
Dividend USD 0.32
02/01/2017
09/23/2016
Dividend USD 0.3
11/08/2016
06/23/2016
Dividend USD 0.3
08/03/2016
04/28/2016
Dividend USD 0.3
05/11/2016
12/16/2015
Dividend USD 0.3
02/03/2016
09/25/2015
Dividend USD 0.28
11/04/2015
06/25/2015
Dividend USD 0.28
08/05/2015
04/23/2015
Dividend USD 0.28
05/06/2015
12/17/2014
Dividend USD 0.28
02/04/2015
10/24/2014
Dividend USD 0.26
11/05/2014
06/26/2014
Dividend USD 0.26
07/30/2014
04/25/2014
Dividend USD 0.26
05/07/2014
12/17/2013
Dividend USD 0.26
02/05/2014
10/25/2013
Dividend USD 0.24
11/06/2013
06/28/2013
Dividend USD 0.24
07/31/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PFE
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Pfizer Inc. stock information, including NYSE:PFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PFE stock methods without spending real money on the virtual paper trading platform.